그레이브스 안병증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Graves Ophthalmopathy Insights and Trends

• According to DelveInsight's analysis, the Graves Ophthalmopathy market size was found to be ~USD 3,500 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Graves' ophthalmopathy is generally considered a rare to infrequent disease, although it affects about 25-50% of patients with Graves' disease.
• According to the European Group on Graves Orbitopathy (EUGOGO) clinical practice guidelines 2021, IV methylprednisolone in combination with oral mycophenolate sodium (or mofetil) represents the first-line treatment for moderate-to-severe and acute Graves ophthalmopathy.
• The only FDA-approved disease-specific therapy is Teprotumumab (TEPEZZA), marketed by Amgen. It is an IGF-1 inhibitor and represents the first targeted therapy that directly addresses disease pathology, showing strong efficacy in reducing proptosis and diplopia in clinical trials.
• Linsitinib's oral administration offers greater convenience than SC and IV therapies, while its approval in Graves' ophthalmopathy supports its established clinical utility and safety profile.
• The pipeline for Graves' ophthalmopathy is highly active and competitive. Key companies include Viridian Therapeutics (elegrobart), Roche (satralizumab), and Sling Therapeutics (linsitinib).

DelveInsight's 'Graves Ophthalmopathy - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Graves ophthalmopathy, historical and forecasted epidemiology, as well as the Graves ophthalmopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Graves Ophthalmopathy market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Graves' ophthalmopathy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Graves' ophthalmopathy and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Graves Ophthalmopathy Market

Rising Disease Prevalence & Awareness

The increasing prevalence of Graves' ophthalmopathy and better diagnostic practices are expanding the patient pool, with improved awareness among clinicians, leading to earlier detection and treatment.

Increased R&D and Strategic Collaborations

Companies like Roche, Amgen, and Sling Therapeutics are investing in innovative delivery methods (subcutaneous, oral) and new drug development.

Graves Ophthalmopathy Understanding and Treatment Algorithm

Graves Ophthalmopathy Overview and Diagnosis

Graves' ophthalmopathy, also known as Thyroid Eye Disease (TED), is an autoimmune inflammatory condition associated with Graves' disease in which immune-mediated activation of orbital fibroblasts leads to expansion of extraocular muscles and orbital fat. This results in characteristic features such as proptosis (eye bulging), eyelid retraction, periorbital edema, and, in severe cases, optic nerve compression. The disease typically follows an active inflammatory phase followed by a chronic fibrotic phase, and its severity can range from mild discomfort to vision-threatening complications. Risk factors include smoking, thyroid dysfunction, and high levels of thyroid-stimulating immunoglobulins.

Diagnosis of Graves' ophthalmopathy is primarily clinical, supported by laboratory and imaging findings. Patients commonly present with eye irritation, redness, diplopia, and progressive proptosis. Thyroid function tests (TSH, free T4, T3) and thyroid antibody levels, particularly TSH receptor antibodies, help confirm the underlying autoimmune thyroid disorder. Imaging studies such as CT or MRI of the orbits are used to assess enlargement of extraocular muscles and orbital tissue involvement, and to rule out other orbital pathologies. Disease activity and severity are often graded using clinical activity scores (CAS), which guide treatment decisions.

Current Graves Ophthalmopathy Treatment Landscape

Management depends on disease severity and activity, combining supportive, medical, and surgical approaches. Mild cases may be managed with lubricants and risk factor control, like smoking cessation, while moderate-to-severe active disease often requires immunosuppression, typically with intravenous corticosteroids such as Methylprednisolone. The only disease-specific approved therapy is TEPEZZA, marketed by Amgen, which targets the IGF-1 receptor and has shown significant efficacy in reducing proptosis and diplopia. Surgical interventions, including orbital decompression, strabismus surgery, or eyelid procedures, are typically reserved for the inactive phase or vision-threatening disease.

Graves' Ophthalmopathy Unmet Needs

The section "unmet needs of Graves' ophthalmopathy" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited treatment options

2. Limitations of guidelines

3. Disease burden

4. Access barriers, and others.....

Graves Ophthalmopathy Epidemiology

Key Findings from Graves Ophthalmopathy Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total prevalent cases of Graves' ophthalmopathy in the 7MM were ~2,408,800.
• In 2025, the United States accounted for approximately 1.03 million diagnosed prevalent cases of Graves' ophthalmopathy, representing the highest disease burden among major markets, followed by the EU4 and the UK, and Japan.
• Graves' ophthalmopathy is significantly more prevalent in females, accounting for approximately 80% of cases, compared with 20% in males.

Graves Ophthalmopathy Drug Analysis & Competitive Landscape

The Graves' ophthalmopathy drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase III-I clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the graves ophthalmopathy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the graves ophthalmopathy therapeutics market.

Approved Therapies for Graves Ophthalmopathy

Teprotumumab (TEPEZZA): Amgen

Teprotumumab, marketed as TEPEZZA, is an insulin-like growth factor-1 receptor (IGF-1R) inhibiting monoclonal antibody originally developed by Horizon Therapeutics and now part of Amgen following its 2023 acquisition. It is the first and only FDA-approved therapy specifically for TED, targeting the underlying autoimmune pathway rather than just symptoms. TEPEZZA has demonstrated strong efficacy in reducing proptosis and diplopia in clinical trials.

Graves Ophthalmopathy Pipeline Analysis

Elegrobart (VRDN-003): Viridian Therapeutics

Elegrobart is an investigational monoclonal antibody developed by Viridian Therapeutics for the treatment of TED. It targets and blocks the IGF-1R, a key pathway involved in the disease process. It is being developed as a potential best-in-class subcutaneous anti-IGF-1R therapy for self-administration at home using a low-volume autoinjector, with every-4-week or every-8-week dosing. The company, in its SEC filing, anticipated that Elegrobart is on track for a BLA submission anticipated in Q1 2027.

Linstinitb: Sling Therapeutics

Linsitinib is developed for TED that will ease the treatment burden for patients, caregivers, and physicians. Linsitinib is the first and only oral small-molecule therapy to establish statistical and clinical significance in TED. Linsitinib works by inhibiting the IGF-1R target, which is the only validated clinical target in TED and the only target for current FDA-approved therapies. Activation of the IGF-1R target leads to inflammation and proptosis seen in TED. Linsitinib has an established safety profile through treatment of more than 900 patients in fifteen clinical trials in multiple diseases.

Graves Ophthalmopathy Key Players, Market Leaders, and Emerging Companies

• Viridian Therapeutics
• Roche
• Sling Therapeutics
• Amgen
• Horizon Therapeutics, and others

Graves Ophthalmopathy Drug Updates

• In March 2026, Viridian Therapeutics announced positive topline data from the elegrobart REVEAL-1 phase III clinical trial in patients with active thyroid eye disease (TED). REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) and Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24.
• In January 2025, Sling Therapeutics announced topline efficacy and safety data from the Phase II/III LIDS trial of linsitinib in patients with active, moderate to severe TED. The trial met the primary endpoint of proptosis reduction with statistical significance at the 150mg BID dose.
• In October 2023, Amgen announced that it had completed its acquisition of Horizon Therapeutics.

Graves Ophthalmopathy Market Outlook

The treatment landscape of Graves' ophthalmopathy has shifted from mainly supportive care and surgery toward disease-modifying immunotherapy. Conventional management includes high-dose intravenous corticosteroids such as Methylprednisolone for active disease. In addition, several off-label biologics, such as Tocilizumab and Rituximab, are used in refractory patients, although they are not specifically approved for TED.

A breakthrough came with the approval of Teprotumumab (TEPEZZA) by Amgen, the first targeted therapy for TED. It inhibits IGF-1R, leading to significant reductions in proptosis and diplopia. The pipeline is expanding with targeted approaches, including IGF-1R antibodies like elegrobart, IL-6 inhibitors such as satralizumab, and oral small molecules like linsitinib.

Overall, the advancements in targeted treatments are expected to drive steady growth in the 7MM Graves' Ophthalmopathy market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of Graves' ophthalmopathy. i.e., USD ~3000 million in 2025.
• Among approved therapies, TEPEZZA is expected to remain the primary revenue driver, supported by its strong efficacy in reducing proptosis and its position as the only disease-specific approved treatment.
• The entry of late to mid-stage candidates such as elegrobart (VRDN-003), satralizumab (RG6168), and linsitinib is anticipated to intensify competition and accelerate the shift toward more convenient subcutaneous and oral targeted therapies over the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Graves Ophthalmopathy (2022-2036 Forecast)

The Graves' ophthalmopathy market comprises targeted immunotherapies, each targeting different aspects of Graves' ophthalmopathy.

• Targeted immunotherapies: Approved therapies such as TEPEZZA and emerging therapies such as elegrobart and linsitnib target the IGF-1R receptor pathway, a key driver of orbital fibroblast activation and tissue expansion in TED, and satralizumab (IL-6 receptor inhibitor) targets inflammatory signaling pathways. Linsitinib is an oral targeted therapy candidate, representing a non-biologic alternative to monoclonal antibodies, and is being developed to improve patient convenience compared to intravenous IGF-1R therapies.

Targeted Immunotherapy defines the core innovation landscape driving market growth.

Graves Ophthalmopathy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the graves ophthalmopathy drug's uptake, performance at peak, factors affecting performance during the prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in Graves' ophthalmopathy is expected to vary based on clinical positioning, mechanism of action, and stage of development. One approved therapy, TEPEZZA, is set to experience moderate but meaningful uptake. Its targeted IGF-1R inhibiting mechanism and demonstrated efficacy in reducing proptosis and diplopia support its use in active moderate-to-severe and refractory cases of Thyroid Eye Disease.

In contrast, pipeline candidates such as elegrobart (VRDN-003), satralizumab (RG6168), and linsitinib are likely to demonstrate progressive uptake upon approval, as these therapies are designed to improve upon existing treatment options by targeting key disease pathways such as IGF-1R signaling and IL-6-mediated inflammatory pathways.

Detailed insights into emerging therapies' drug uptake are included in the report

Graves Ophthalmopathy Therapies Price Scenario & Trends

Pricing and analogue assessment of Graves' ophthalmopathy therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Graves Ophthalmopathy Approved Drugs

The recommended dosing regimen for TEPEZZA consists of an initial intravenous infusion of 10 mg/kg, followed by 20 mg/kg administered every three weeks for a total of seven additional infusions. The total treatment cost is approximately USD 350,000 for a 75 kg patient.

Industry Experts and Physician Views for Graves Ophthalmopathy

To keep up with Graves' ophthalmopathy market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Graves' ophthalmopathy emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Graves' ophthalmopathy, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as the Institute for Genomic Sciences, Florida International University, and Essen University Hospital, etc. were contacted. Their opinion helps understand and validate current and emerging Graves' ophthalmopathy therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Graves ophthalmopathy.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Graves' ophthalmopathy, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Graves' ophthalmopathy, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Graves' ophthalmopathy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Graves' Ophthalmopathy market.

Report Insights

• Graves Ophthalmopathy Patient Population Forecast
• Graves Ophthalmopathy Therapeutics Market Size
• Graves Ophthalmopathy Pipeline Analysis
• Graves Ophthalmopathy Market Size and Trends
• Graves Ophthalmopathy Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Graves Ophthalmopathy Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Graves Ophthalmopathy Treatment Addressable Market (TAM)
• Graves Ophthalmopathy Competitive Landscape
• Graves Ophthalmopathy Major Companies Insights
• Graves Ophthalmopathy Price Trends and Analogue Assessment
• Graves Ophthalmopathy Therapies Drug Adoption/Uptake
• Graves Ophthalmopathy Therapies Peak Patient Share Analysis

Report Assessment

• Graves Ophthalmopathy Current Treatment Practices
• Graves' Ophthalmopathy Unmet Needs
• Graves Ophthalmopathy Clinical Development Analysis
• Graves Ophthalmopathy Emerging Drugs Product Profiles
• Graves Ophthalmopathy Market Attractiveness
• Graves Ophthalmopathy Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the Graves' ophthalmopathy market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Graves' ophthalmopathy?
• What are the disease risks, burdens, and unmet needs of Graves' ophthalmopathy? What will be the growth opportunities across the 7MM concerning the patient population with Graves' ophthalmopathy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Graves' ophthalmopathy? What are the current guidelines for treating Graves' ophthalmopathy in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Graves' ophthalmopathy market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of Graves Ophthalmopathy

6. Graves Ophthalmopathy Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Graves Ophthalmopathy by Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Graves Ophthalmopathy by Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Graves Ophthalmopathy

• 7.1. Introduction
• 7.2. Types of Graves Ophthalmopathy
• 7.3. Causes
• 7.4. Signs And Symptoms
• 7.5. Diagnosis
  • 7.5.1. Differential Diagnosis
  • 7.5.2. Diagnostic Algorithm
  • 7.5.3. Diagnostic Guidelines

8. Epidemiology and Patient Population of Graves Ophthalmopathy

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Prevalent Cases of Graves Ophthalmopathy in the 7MM
• 8.4. The United States
  • 8.4.1. Total Prevalent Cases of Graves Ophthalmopathy in the United States
  • 8.4.2. Diagnosed Prevalent Cases of Graves Ophthalmopathy in the United States
  • 8.4.3. Gender-specific Prevalent Cases of Graves Ophthalmopathy in the United States
  • 8.4.4. Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in the United States
  • 8.4.5. Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy by Severity in the United States
  • 8.4.6. Acute moderate-to-severe Drug-treated Prevalent Cases of Graves Ophthalmopathy in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Prevalent Cases of Graves Ophthalmopathy in EU4 and the UK
  • 8.5.2. Diagnosed Prevalent Cases of Graves Ophthalmopathy in EU4 and the UK
  • 8.5.3. Gender-specific Prevalent Cases of Graves Ophthalmopathy in EU4 and the UK
  • 8.5.4. Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in EU4 and the UK
  • 8.5.5. Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy by Severity in EU4 and the UK
  • 8.5.6. Acute moderate-to-severe Drug-treated Prevalent Cases of Graves Ophthalmopathy in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Prevalent Cases of Graves Ophthalmopathy in Japan
  • 8.6.2. Diagnosed Prevalent Cases of Graves Ophthalmopathy in Japan
  • 8.6.3. Gender-specific Prevalent Cases of Graves Ophthalmopathy in Japan
  • 8.6.4. Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in Japan
  • 8.6.5. Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy by Severity in Japan
  • 8.6.6. Acute moderate-to-severe Drug-treated Prevalent Cases of Graves Ophthalmopathy in Japan

9. Patient Journey of Graves Ophthalmopathy

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Graves Ophthalmopathy
• 10.2. Teprotumumab (TEPEZZA): Amgen
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of Graves Ophthalmopathy
• 11.2. Elegrobart (VRDN-003): Viridian Therapeutics
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. Satralizumab (RG6168): Roche
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
    • 11.3.3.1. Clinical Trial Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst Views
• 11.4. Linsitinib: Sling Therapeutics
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
    • 11.4.3.1. Clinical Trial Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analyst Views

12. Graves Ophthalmopathy: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Graves Ophthalmopathy
• 12.3. Conjoint Analysis of Graves Ophthalmopathy
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Graves Ophthalmopathy in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of Graves Ophthalmopathy in the United States
  • 12.6.2. Market Size of Graves Ophthalmopathy by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Graves Ophthalmopathy in EU4 and the UK
  • 12.7.2. Market Size of Graves Ophthalmopathy by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Graves Ophthalmopathy in Japan
  • 12.8.2. Market Size of Graves Ophthalmopathy by Therapies in Japan

13. Unmet Needs of Graves Ophthalmopathy

14. SWOT Analysis of Graves Ophthalmopathy

15. KOL Views of Graves Ophthalmopathy

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Graves Ophthalmopathy

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Market Access and Reimbursement of Graves Ophthalmopathy Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight